Sapian™ Scales Further: Pre-Validated Targets, Zero R&D Risk

From pre-validated hard-to-drug targets to risk-free partnerships
Artificial Intelligence Biotechnology Pharma
Wed 04 Nov 2026
Sapian™ Scales Further: Pre-Validated Targets, Zero R&D Risk

Brussels, Belgium — A few years ago, Kantify started working on a bet: that you don't need a crystal structure to drug the undruggable. That bet turned into Sapian™, a non-structure-based AI engine that screens over 20 billion molecules in under 24 hours. And after several in vitro validations across targets where most pipelines fail or recycle known chemistry, Kantify is ready to open it up.

Kantify is inviting first-wave partners to explore a pre-engineered portfolio of novel small molecules for high-value GPCR and ion channel targets, delivered under a framework designed to keep the risk away from your R&D budget.

This had been made possible thanks to the latest investments in Sapian™; its new API makes everything faster, auditable and more scalable without demanding constant hand tuning. This latest Sapian™ is currently used with first moving partners.

Portfolio Scope

  • Validated hit series on Cav3.1, Nav1.4, Nav1.8, and hard-to-drug GPCRs. List available under NDA.

  • Each program delivers multiple novel chemotypes, not a single scaffold. If one path hits a dead end, there are others.

  • Everything is pre-screened computationally for off-target liabilities and synthetic feasibility before it reaches a lab.

  • Powered by the same engine that's already delivered for top-10 pharma collaborators.

How it works

  • Our partner gets validated starting points, backed by independent in vitro data. Full R&D sovereignty. No early-stage exploration cost, no technical failure risk.

  • Scaffolds come pre-screened for synthetic accessibility, so there's no hit-to-lead delay.

Two tracks

This wave focuses on a pre-engineered portfolio of high-value targets. But if your team has a priority target outside that set, the same engine is available on a custom basis, delivering orthogonal hit series engineered to your profile.

Drugging intractable targets shouldn't require biopharma partners to absorb years of early-stage attrition risk. By expanding our commercial strategy to offer a pre-validated portfolio of high-value small molecule GPCR and ion channel targets, we provide immediate, risk-free access to novel chemical space while keeping our custom, on-demand AI discovery programs fully available for partner-specified targets.

— Ségolene Martin, CEO of Kantify

Want to explore a partnership? Contact Kantify's partnering team.

About Kantify

Kantify is an AI-native biopharmaceutical company headquartered in Brussels, Belgium. Driven by its proprietary Sapian™ AI platform, Kantify discovers novel small-molecule therapeutics for hard-to-drug targets.